RFK Jr. Appoints Majority of Peptide-Industry Tied Members to FDA Compounding Panel
Wednesday, July 1st, 2026 - Health and Human Services Secretary Robert F. Kennedy Jr. has appointed eight new members to a Food and Drug Administration advisory committee that will decide whether compounding pharmacies can manufacture certain peptides, with a majority of the appointees having financial ties to the peptide compounding industry, according to a report from Protect Our Care, a health care advocacy group.
The appointments come ahead of a scheduled FDA advisory committee meeting where agency scientists are expected to recommend against adding seven "wellness" peptides to the list of products eligible for compounding, citing a lack of clinical evidence and human trial data supporting their safety and effectiveness.
Conflict of Interest Concerns
Protect Our Care, citing reporting from STAT, said that most of the newly appointed committee members are either linked to peptide compounders or have publicly supported broader access to unregulated peptide products. The advocacy group characterized the appointments as prioritizing commercial interests over public safety.
FDA scientists have flagged concerns about the safety profile of the peptides in question, noting that some have not been studied in humans, according to documents reviewed by multiple news organizations including NBC News and The Washington Post.
Regulatory Flashpoint
The compounding advisory committee's upcoming meeting represents a potential flashpoint between FDA career scientists and political appointees aligned with Kennedy's "Make America Healthy Again" agenda, which has advocated for deregulating access to peptide products.
The FDA has previously issued warning letters to compounding pharmacies for manufacturing peptide products without appropriate oversight, and the agency recently set impurity thresholds as low as 0.10% for certain peptide products, according to an analysis by Oath Research.
Broader Context
The controversy over peptide regulation has intensified as unregulated peptide products marketed for weight loss, anti-aging, and wellness purposes have grown in popularity. The FDA has maintained that many of these products lack sufficient evidence of safety and efficacy, while Kennedy has pushed for expanded access.
The compounding committee's recommendations, while not binding, carry significant weight in FDA decision-making about which drugs can be compounded without individual patient-specific prescriptions.
